# Setting Endotoxin Limits During Development of Investigational Oncology Drugs and Biological Products Guidance for Industry: Draft Guidance for Industry - FDA Guidance Document Source: https://www.globalkeysolutions.net/guidances/guidance-document/setting-endotoxin-limits-during-development-of-investigational-oncology-drugs-and-biological-products-guidance-for-industry-draft-guidance-for-industry/ef751a3a-e9d6-4489-b86d-73f2411682c1 > FDA guidance document: Setting Endotoxin Limits During Development of Investigational Oncology Drugs and Biological Products Guidance for Industry: Draft Guidance for Industry. Issue date: July 28, 2020. Get complete insights and analysis. --- ## Details - Title: Setting Endotoxin Limits During Development of Investigational Oncology Drugs and Biological Products Guidance for Industry: Draft Guidance for Industry - Communication Type: Guidance Document - Product Type: biologics - Office Name: Center for Drug Evaluation and Research - Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c - Issue Date: 2020-07-28 - Comment Close Date: 2020-10-28 - Last Changed: 2020-09-01 - Docket Number: FDA-2020-D-1294 ## Related Documents - [Master Protocols for Drug and Biological Product Development](https://www.globalkeysolutions.net/guidances/guidance-document/master-protocols-for-drug-and-biological-product-development/401e65ec-7388-4389-a95a-dc8860a1ce51) - [Labeling for Biosimilar and Interchangeable Biosimilar Products](https://www.globalkeysolutions.net/guidances/guidance-document/labeling-for-biosimilar-and-interchangeable-biosimilar-products/54a5f712-03f5-4993-b0d7-6a1c2f261eff) - [Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/acute-myeloid-leukemia-developing-drugs-and-biological-products-for-treatment-draft-guidance-for-industry/8143a606-18fc-488c-b3ab-4c23bdcd999a)